Davenport & CO LLC Genmab A/S Transaction History

Davenport & CO LLC

$16.8 Billion
Q3 2024

A detailed history of Davenport & CO LLC transactions in Genmab A/S stock. As of the latest transaction made, Davenport & CO LLC holds 33,262 shares of GMAB stock, worth $686,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,262

Previous 33,484 0.66%

Holding current value

$686,860

Previous $841,000 3.69%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$23.84 - $28.48 $5,292 - $6,322	-222 Reduced 0.66%	33,262 $810,000
Q2 2024 Aug 06, 2024	SELL	$25.13 - $30.27 $56,894 - $68,531	-2,264 Reduced 6.33%	33,484 $841,000
Q1 2024 May 03, 2024	BUY	$26.43 - $32.77 $48,974 - $60,722	1,853 Added 5.47%	35,748 $1.07 Million
Q4 2023 Jan 23, 2024	SELL	$27.94 - $35.44 $194,630 - $246,875	-6,966 Reduced 17.05%	33,895 $1.08 Million
Q3 2023 Oct 17, 2023	BUY	$35.27 - $42.24 $1.44 Million - $1.73 Million	40,861 New	40,861 $1.44 Million
Q4 2022 Jan 20, 2023	BUY	$33.8 - $47.06 $26,025 - $36,236	770 Added 8.64%	9,677 $0
Q3 2022 Oct 11, 2022	SELL	$31.52 - $373.61 $75,175 - $891,059	-2,385 Reduced 21.12%	8,907 $286,000
Q2 2022 Jul 18, 2022	SELL	$26.83 - $38.57 $21,464 - $30,856	-800 Reduced 6.62%	11,292 $367,000
Q1 2022 May 02, 2022	SELL	$30.95 - $39.68 $103,589 - $132,808	-3,347 Reduced 21.68%	12,092 $437,000
Q4 2021 Feb 10, 2022	BUY	$35.87 - $47.12 $11,550 - $15,172	322 Added 2.13%	15,439 $611,000
Q3 2021 Oct 14, 2021	BUY	$41.55 - $48.72 $64,153 - $75,223	1,544 Added 11.38%	15,117 $661,000
Q2 2021 Jul 28, 2021	BUY	$32.88 - $44.57 $446,280 - $604,948	13,573 New	13,573 $554,000

Others Institutions Holding GMAB

# of Institutions

238

Shares Held

52.6M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.

Account